The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinical Infectious Diseases

• Publication date

  2004-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1086/381678PMID 14986261
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients

  2004cited by this paper
• Acidose lactique sévère chez les patients infectés par le VIH traités par inhibiteurs nucléosidiques de la reverse transcriptase : 9 cas

  2003cited by this paper
• Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study.

  2003cited by this paper
• Metabolism of Tenofovir and Didanosine in Quiescent or Stimulated Human Peripheral Blood Mononuclear Cells

  2003cited by this paper
• Nucleoside analogues and neuropathy in the era of HAART.

  2003cited by this paper
• Nucleoside analogues and HIV: the combined cost to mitochondria.

  2003cited by this paper
• Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial.

  2003cited by this paper
• Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy

  2003cited by this paper
• [Severe lactic acidosis in HIV-infected patients treated with nucleosidic reverse transcriptase analogs: a report of 9 cases].

  2003cited by this paper
• HIV infection and lipodystrophy.

  2003cited by this paper
• Long-term complications of nucleoside reverse transcriptase inhibitor therapy.

  2003cited by this paper
• Incidence of and Risk Factors for Lipoatrophy (Abnormal Fat Loss) in Ambulatory HIV-1-Infected Patients

  2003influential reference
• Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals

  2003influential reference
• Organic anion transporting polypeptides, cholestasis, and nuclear receptors

  2002cited by this paper
• Development of Enzymatic Assays for Quantification of Intracellular Lamivudine and Carbovir Triphosphate Levels in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected Patients

  2002cited by this paper
• TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy.

  2002cited by this paper
• Reduction of Inflammatory Cytokine Concentrations and Improvement of Endothelial Functions in Obese Women After Weight Loss Over One Year

  2002cited by this paper
• Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors

  2002cited by this paper
• Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients.

  2002cited by this paper
• Conceptual models for implementing biopsychosocial theory in clinical practice.

  2002cited by this paper
• Increased serum interferon alpha in HIV–1 associated lipodystrophy syndrome

  2002cited by this paper
• Intracellular carbovir triphosphate levels in patients taking abacavir once a day.

  2002cited by this paper
• TNF-α promoter region gene polymorphisms in HIV-positive patients with lipodystrophy

  2002cited by this paper
• Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules

  2002cited by this paper
• Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea

  2002cited by this paper
• Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance.

  2002cited by this paper
• Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.

  2002cited by this paper
• Lipodystrophy in Human Immunodeficiency Virus-Infected Patients

  2002cited by this paper
• Lack of Correlation between Length Variation in the DNA Polymerase γ Gene CAG Repeat and Lactic Acidosis or Neuropathy during Antiretroviral Treatment

  2002cited by this paper
• Lack of correlation between length variation in the DNA polymerase gamma gene CAG repeat and lactic acidosis or neuropathy during antiretroviral treatment.

  2002cited by this paper
• Risk factors for the HIV‐associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment

  2002influential reference
• Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer.

  2002cited by this paper
• Body Habitus Changes and Metabolic Alterations in Protease Inhibitor‐Naive HIV‐1‐Infected Patients Treated With Two Nucleoside Reverse Transcriptase Inhibitors

  2002cited by this paper
• Improved method for the simultaneous determination of d4T, 3TC and ddl intracellular phosphorylated anabolites in human peripheral-blood mononuclear cells using high-performance liquid chromatography/tandem mass spectrometry.

  2002cited by this paper
• Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

  2002cited by this paper
• Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients.

  2002cited by this paper
• Risk of HAART therapy in hepatitis C

  2002cited by this paper
• HIV-1/AIDS and maternal and child health in Africa.

  2002cited by this paper
• Long‐term Exposure to Lifelong Therapies

  2002cited by this paper
• Hyperlactatemia syndromes in people with HIV infection

  2002cited by this paper
• Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection.

  2002cited by this paper
• Identifying and managing morphologic complications of HIV and HAART.

  2002cited by this paper
• [Chronic hepatitis C in HIV-HCV coinfected patients].

  2002cited by this paper
• Clinical assessment of HIV-associated lipodystrophy in an ambulatory population

  2001influential reference
• Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders?

  2001cited by this paper
• Zidovudine phosphorylation and mitochondrial toxicity in vitro.

  2001cited by this paper
• Toxicity of Antiviral Nucleoside Analogs and the Human Mitochondrial DNA Polymerase*

  2001influential reference
• The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals

  2001cited by this paper
• Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy

  2001cited by this paper
• Lipodystrophic Syndromes and Hyperlipidemia in a Cohort of HIV‐1‐Infected Patients Receiving Triple Combination Antiretroviral Therapy With a Protease Inhibitor

  2001cited by this paper
• Peripheral neuropathy and antiretroviral drugs

  2001cited by this paper
• Mitochondrial Alterations with Mitochondrial DNA Depletion in the Nerves of AIDS Patients with Peripheral Neuropathy Induced by 2′3′-Dideoxycytidine (ddC)

  2001cited by this paper
• Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus–infected patients with congenital coagulation disorders

  2001cited by this paper
• Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.

  2001cited by this paper
• Lipodystrophy in 685 HIV-1–Treated Patients: Influence of Antiretroviral Treatment and Immunovirological Response

  2001cited by this paper
• Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil).

  2001cited by this paper
• Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases.

  2001cited by this paper
• Sex differences in HAART-associated dyslipidaemia

  2001cited by this paper
• Mitochondrial DNA Depletion, Oxidative Stress, and Mutation: Mechanisms 0f Dysfunction from Nucleoside Reverse Transcriptase Inhibitors

  2001cited by this paper
• HIV neuropathy: Insights in the pathology of HIV peripheral nerve disease

  2001cited by this paper
• Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon‐α therapy

  2001cited by this paper
• Antiretroviral Therapy and the Lipodystrophy Syndrome

  2001cited by this paper
• Macrophages require different nucleoside transport systems for proliferation and activation

  2001cited by this paper
• Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database

  2001cited by this paper
• Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.

  2001cited by this paper
• Combined Antiretroviral Therapy Causes Cardiomyopathy and Elevates Plasma Lactate in Transgenic AIDS Mice

  2001cited by this paper
• Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.

  2001cited by this paper
• Phosphorylation of Nucleoside Analog Antiretrovirals: A Review for Clinicians

  2001cited by this paper
• Zidovudine Phosphorylation Determined Sequentially over 12 Months in Human Immunodeficiency Virus-Infected Patients with or without Previous Exposure to Antiretroviral Agents

  2001influential reference
• Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine.

  2000cited by this paper
• Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy?

  2000cited by this paper
• Differences Between Women and Men in Adverse Events and CD4+ Responses to Nucleoside Analogue Therapy for HIV Infection

  2000cited by this paper
• Leptin in the regulation of immunity, inflammation, and hematopoiesis

  2000cited by this paper
• Association of Severe Insulin Resistance With Both Loss of Limb Fat and Elevated Serum Tumor Necrosis Factor Receptor Levels in HIV Lipodystrophy

  2000cited by this paper
• Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases.

  2000cited by this paper
• Simultaneous Quantitation of Intracellular Zidovudine and Lamivudine Triphosphates in Human Immunodeficiency Virus-Infected Individuals

  2000cited by this paper
• Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea

  2000influential reference
• Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection

  2000influential reference
• Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome.

  2000cited by this paper
• The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells.

  2000cited by this paper
• Human leptin enhances activation and proliferation of human circulating T lymphocytes.

  2000cited by this paper
• Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity.

  2000influential reference
• Is there a relationship between hepatitis C virus infection and antiretroviral-associated lipoatrophy?

  2000cited by this paper
• Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

  2000cited by this paper
• Normalization of Immune Activation in Lymphoid Tissue Following Highly Active Antiretroviral Therapy

  2000cited by this paper
• Toxicity of Antiretroviral Nucleoside and Nucleotide Analogues

  2000cited by this paper
• Adipose redistribution in human immunodeficiency virus-seropositive patients: association with CD4 response.

  2000cited by this paper
• Zidovudine triphosphate and lamivudine triphosphate concentration–response relationships in HIV-infected persons

  2000cited by this paper
• Tumor necrosis factor‐α regulates secretion of the adipocyte‐derived cytokine, leptin

  2000cited by this paper
• Adverse effects of antiretroviral therapy.

  2000cited by this paper
• Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus–associated lipodystrophy syndrome

  2000cited by this paper
• Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team.

  2000cited by this paper
• Relationship between plasma leptin levels and the tumor necrosis factor-α system in obese subjects

  1999cited by this paper
• Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.

  1999cited by this paper
• Relationship between plasma leptin levels and the tumor necrosis factor-alpha system in obese subjects.

  1999cited by this paper
• CD69, CD25, and HLA-DR activation antigen expression on CD3+ lymphocytes and relationship to serum TNF-alpha, IFN-gamma, and sIL-2R levels in aging.

  1999cited by this paper
• A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

  1998cited by this paper
• Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000

  1998cited by this paper
• Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro.

  1998cited by this paper
• A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection.

  1998cited by this paper

• Cellular pharmacology of tenofovir alafenamide and emtricitabine in neutrophils and platelets in people with and without HIV.

  2025cites this paper
• Overview of methods that determine mitochondrial function in human disease

  2025cites this paper
• Identification of a novel small-molecule inhibitor of the HIV-1 reverse transcriptase activity with a non-nucleoside mode of action

  2025cites this paper
• Modeling of HIV‐1 prophylactic efficacy and toxicity with islatravir shows non‐superiority for oral dosing, but promise as a subcutaneous implant

  2024cites this paper
• Selectively T cell phosphorylation activation of azvudine in the thymus tissue with immune protection effect

  2024cites this paper
• Modeling of HIV-1 prophylactic efficacy and toxicity with Islatravir shows non-superiority for oral dosing, but promise as a subdermal implant

  2024cites this paper
• A Cross-Biomeasure Study to Optimize Antiretroviral Adherence Estimation

  2024cites this paper
• Advances in Antiviral Delivery Systems and Chitosan-Based Polymeric and Nanoparticulate Antivirals and Antiviral Carriers

  2023cites this paper
• HIV nucleoside reverse transcriptase inhibitors.

  2022cites this paper
• Comparison of the Effects of Three Dual-Nucleos(t)ide Reverse Transcriptase Inhibitor Backbones on Placenta Mitochondria Toxicity and Oxidative Stress Using a Mouse Pregnancy Model

  2022cites this paper
• Chemical derivatization as a novel strategy for selective and sensitive determination of intracellular di-and triphosphate anabolites in peripheral blood mononuclear cells.

  2022cites this paper
• Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies

  2022cites this paper
• Antiretroviral Therapy – Nucleoside/Nucleotide and Non-Nucleoside Reverse Transcriptase Inhibitors

  2021cites this paper
• Impact of long-term antiretroviral therapy on gut and oral microbiotas in HIV-1-infected patients

  2021cites this paper
• Reverse phase-liquid chromatography assisted protocol for simultaneous determination of lamivudine and tenofovir disoproxil fumarate in combined medication used to control HIV infection: an investigative approach

  2021influential citation
• Impact of long-term antiretroviral therapy on gut and oral microbiotas in HIV-1-infected patients

  2021cites this paper
• REverSe TRanscrIptase chain termination (RESTRICT) for selective measurement of nucleotide analogs used in HIV care and prevention

  2021cites this paper
• COX

  2020cites this paper
• Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine

  2020cites this paper
• Inhibition of human immunodeficiency virus type 1 by niclosamide through mTORC1 inhibition

  2020cites this paper
• In utero exposure to protease inhibitor-based antiretroviral regimens delays growth and developmental milestones in mice

  2020cites this paper
• Population pharmacokinetic and machine learning methods to increase precision of adherence assessments for HIV prevention

  2019cites this paper
• Design, synthesis and antiviral evaluation of novel acyclic phosphonate nucleotide analogs with triazolo[4,5-b]pyridine, imidazo[4,5-b]pyridine and imidazo[4,5-b]pyridin-2(3H)-one systems

  2019cites this paper
• DNA polymerase-γ hypothesis in nucleoside reverse transcriptase-induced mitochondrial toxicity revisited: A potentially protective role for citrus fruit-derived naringenin?

  2019cites this paper
• Symptoms of toxicity and plasma cytochrome c levels in human immunodeficiency virus-infected patients receiving anti-retroviral therapy in Ghana: A cross-sectional study.

  2018cites this paper
• Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial

  2018cites this paper
• Precision medicine for HIV: where are we?

  2018cites this paper
• Bioanalysis and pharmacokinetics-pharmacodynamics modeling of the endogenous 2'deoxynucleoside triphosphate pool in individuals receiving tenofovir/emtricitabine

  2017cites this paper
• Repurposing of nucleoside- and nucleobase-derivative drugs as antibiotics and biofilm inhibitors

  2017cites this paper
• The ProTide Prodrug Technology: From the Concept to the Clinic

  2017cites this paper
• Beyond the polymerase-γ theory: Production of ROS as a mode of NRTI-induced mitochondrial toxicity

  2017cites this paper
• Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML.

  2017cites this paper
• UvA-DARE ( Digital Academic Repository ) Beyond the polymerase-γ theory Production of ROS as a mode of NRTI-induced mitochondrial toxicity

  2017cites this paper
• Current Progress in the Pharmacogenetics of Infectious Disease Therapy

  2017cites this paper
• Multiscale Systems‐Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV‐1

  2016cites this paper
• Synthesis, antiviral, cytotoxic and cytostatic evaluation of N1-(phosphonoalkyl)uracil derivatives

  2016cites this paper
• An Organic Anion Transporter 1 (OAT1)-centered Metabolic Network *

  2016cites this paper
• p16INK4a, a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV‐Infected Subjects

  2016cites this paper
• Tenofovir/Emtricitabine Metabolites and Endogenous Nucleotide Exposures are associated with p16INK4a Expression in Subjects on Combination Therapy

  2016cites this paper
• Effect of Chelidonium majus on Metabolic Abnormalities Induced by HAART in Mice

  2016cites this paper
• Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells

  2015cites this paper
• Lentivirus-mediated Gene Transfer in Hematopoietic Stem Cells Is Impaired in SHIV-infected, ART-treated Nonhuman Primates.

  2015cites this paper
• Cardiomyocytes are Protected from Antiretroviral Nucleoside Analog-Induced Mitochondrial Toxicity by Overexpression of PGC-1α

  2015cites this paper
• Phosphonylated 8-Azahypoxantines as Acyclic Nucleotide Analogs

  2015cites this paper
• Pharmacogenetics as a tool to tailor antiretroviral therapy: A review.

  2015cites this paper
• Quantitation of endogenous nucleoside triphosphates and nucleosides in human cells by liquid chromatography tandem mass spectrometry

  2015cites this paper
• Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures

  2014cites this paper
• Tempol protects cardiomyocytes from nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity.

  2014cites this paper
• SAMHD1 Has Differential Impact on the Efficacies of HIV Nucleoside Reverse Transcriptase Inhibitors

  2014cites this paper
• SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase

  2014cites this paper
• Drug-drug interactions in HIV positive cancer patients.

  2014cites this paper
• Pharmacokinetics of two common antiretroviral regimens in older HIV‐infected patients: a pilot study

  2013cites this paper
• Impact of membrane transporters polymorphisms on nucleoside-derived drug bioavailability and action = Impacte dels polimorfismes en transportadors de membrana en la biodisponibilitat i acció de fàrmacs anàlegs de nucleòsids

  2013cites this paper
• BMS-986001, an HIV Nucleoside Reverse Transcriptase Inhibitor, Does Not Degrade Mitochondrial DNA in Long-Term Primary Cultures of Cells Isolated from Human Kidney, Muscle, and Adipose Tissue

  2013cites this paper
• QUANTITATIVE ASSESSMENT OF THE PREVALENCE OF MITOCHONDRIAL TOXICITY IN HIV/AIDS PATIENTS INITIATED ON A STAVUDINE CONTAINING REGIMEN IN MOUNT AYLIFF HOSPITAL ARV CLINIC

  2013cites this paper
• Evaluation of side effects events peripheral neuropathy and lipodystrophy in patients with HIV/AIDS who used stavudine in antiretroviral regimens

  2013cites this paper
• Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.

  2013cites this paper
• Mitochondrial DNA Subhaplogroups L0a2 and L2a Modify Susceptibility to Peripheral Neuropathy in Malawian Adults on Stavudine Containing Highly Active Antiretroviral Therapy

  2013cites this paper
• Antiretrovirals for HIV Exposure Prophylaxis.

  2012cites this paper
• Iatrogenic mitochondriopathies: a recent lesson from nucleoside/nucleotide reverse transcriptase inhibitors.

  2012cites this paper
• A Pilot Study to Assess Inflammatory Biomarker Changes When Raltegravir is Added to a Virologically Suppressive Haart Regimen in HIV-1-Infected Patients with Limited Immunological Responses

  2012cites this paper
• Protein adducts from the anti-HIV drug abacavir - possible biomarkers of drug toxicity

  2012cites this paper
• Una propuesta de manejo práctico del paciente coinfectado en el medio penitenciario

  2012cites this paper
• POPULATION PHARMACOKINETICS OF ANTIRETROVIRAL AGENTS: AN OVERVIEW

  2012cites this paper
• Measuring apparent oxidative damage to mitochondrial DNA by HIV antiretroviral therapy

  2012cites this paper
• Stochastic modeling of mitochondrial polymerase gamma replication and novel algorithms to enrich rare disease alleles and detect tumor somatic mutations in deep sequencing data

  2012cites this paper
• The toxicogenetics of antiretroviral therapy: the evil inside.

  2011cites this paper
• Association of Thymidylate Synthase Gene Polymorphisms with Stavudine Triphosphate Intracellular Levels and Lipodystrophy

  2011cites this paper
• Plasma and Intracellular Tenofovir Pharmacokinetics in the Neonate (ANRS 12109 Trial, Step 2)

  2011cites this paper
• 20 – Current Progress in the Pharmacogenetics of Infectious Disease Therapy

  2011cites this paper
• Drug uptake transporters in antiretroviral therapy.

  2011cites this paper
• Pharmacodynamic Properties Replication with Excellent Pharmacokinetic Potent Inhibitor of Hepatitis C Virus-Methyl Guanosine , Is a C-′-Methyl-2 O 6-INX-08189 , a Phosphoramidate Prodrug of

  2011cites this paper
• INX-08189, a Phosphoramidate Prodrug of 6-O-Methyl-2′-C-Methyl Guanosine, Is a Potent Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic and Pharmacodynamic Properties

  2011cites this paper
• Association of thymidylate synthase gene polymorphisms with

  2011cites this paper
• Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.

  2011cites this paper
• Safety, Tolerability, and Pharmacokinetics of KP-1461 in Phase I Clinical Studies

  2011cites this paper
• Highly Active Antiretroviral Therapy (HAART) and Metabolic Complications

  2011cites this paper
• Very High Concentrations of Active Intracellular Phosphorylated Emtricitabine in Neonates (ANRS 12109 Trial, Step 2)

  2011cites this paper
• Analysis of enzyme kinetic data for mtDNA replication.

  2010cites this paper
• Determinants of Individual Variation in Intracellular Accumulation of Anti-HIV Nucleoside Analog Metabolites

  2010cites this paper
• Cardiovascular Toxicities of Life‐Saving Drugs: Antiviral Therapy

  2010cites this paper
• Zidovudine and Lamivudine for HIV Infection.

  2010cites this paper
• Pharmacogenetics of antiretrovirals.

  2010cites this paper
• Relationship between HIV/Highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens.

  2010cites this paper
• Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action

  2010cites this paper
• Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study

  2010cites this paper
• Differences in cytosolic and mitochondrial 5'-nucleotidase and deoxynucleoside kinase activities in Sprague-Dawley rat and CD-1 mouse tissues: implication for the toxicity of nucleoside analogs in animal models.

  2010cites this paper
• Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine

  2010influential citation
• Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients

  2010cites this paper
• The impact of pharmacogenetics on HIV therapy

  2009cites this paper
• Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV‐Coinfected Ghanaian Patients: UGT2B7*1c Is Associated With Faster Zidovudine Clearance and Glucuronidation

  2009cites this paper
• Fatal lactic acidosis precipitated by nifedipine in a patient treated with disulfiram and antiretrovirals.

  2009cites this paper
• Uptake Transporters of Nucleoside-Derived Anti-HIV Drugs: Expression and Functional Analysis in Immune Cells

  2009cites this paper
• Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms?

  2009influential citation
• Metabolism of Antiviral Nucleosides and Nucleotides

  2009cites this paper
• Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy.

  2009cites this paper
• Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy.

  2009cites this paper
• Long term adverse effects related to nucleoside reverse transcriptase inhibitors: Clinical impact of mitochondrial toxicity

  2009influential citation
• Antiretroviral medication adherence and the development of class-specific antiretroviral resistance

  2009cites this paper
• An Analysis of Enzyme Kinetics Data for Mitochondrial DNA Strand Termination by Nucleoside Reverse Transcription Inhibitors

  2009cites this paper